Lonnie Moulder is the Founder and Managing Member of Tellus BioVentures, an early-stage life sciences investment fund. He is the Founder and Executive Chair for Zenas BioPharma and the founding investor and board Chair for Interius BioTherapeutics, Dianthus Therapeutics and TamuroBio. He previously served as CEO and Director of Tesaro, a biotechnology company he cofounded that was acquired by GSK in 2019. Lonnie earlier served as President and CEO of Abraxis BioScience before the company’s eventual acquisition by Celgene Corporation and as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA where he served as President and CEO.

Lonnie began his career as a clinical pharmacist followed by a seventeen-year career at predecessor companies of Sanofi. Lonnie is a Temple University Trustee, Chair of the Trustee Committee for Research, Chair of the Temple University Japan (TESS) Board and serves on the board of the Fox Chase Cancer Center. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Lonnie also serves on the boards of Zai Lab, Helsinn Healthcare, Aegle Therapeutics, and as board Chair for Trevena. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.